Kailera Therapeutics licensed its portfolio of metabolic disorder drugs from Hengrui. The most advanced program has results from a Phase 2 test in China suggesting it could be competitive with other medications that target the GLP-1 and GIP receptors to trigger weight loss.
The post Metabolic Meds Biotech Kailera Launches With $400M for Next-Generation Weight-Loss Drugs appeared first on MedCity News.
